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Physalin D was isolated from the methanol extract of Physalis alkekengi L. fruits by combination of dif-
ferent chromatographic methods (CPC, TLC, HPLC). The structure was elucidated based on 1H and 13C 
NMR spectral analysis with the aid of 2D-correlation spectroscopy (1H, 1H-COSY, HSQC and HMBC) 
and comparison with literature data. The quantity of physalin D in mature and immature fruits and calyces 
was determined by RP-HPLC-UV method. Among the studied samples, immature calyx showed the high-
est content of physalin D (0.7880 ± 0.0612%), while mature calyx contained 4 times less amount 
(0.2028 ± 0.016%). The physalin D content of the fruit was much lower; immature fruits contained 
0.0992 ± 0.0083% physalin D and mature fruits 0.0259 ± 0.0021%. The antiproliferative activity of the 
CHCl3 extract and its fractions was tested on three cancer cell lines (HeLa, MCF-7 and A431). The anti-
proliferative activity of physalin D is discussed with regard the published data.
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INTRODUCTION
The genus Physalis, which belongs to the family Solanaceae, includes about 120 spe-
cies, mainly distributed in Mexico, Europe, and Southeast and Central Asia. The fruit 
of the most widely used plant Ph. alkekengi var. franchetii (Mast) Makino (Chinese 
lantern) is popular as fruit and food additive, and is also used in the traditional 
Chinese medicine for the treatment of different diseases [25]. Ph. alkekengi L., 
known as “winter cherry” grows in western-Asia, Middle- and South-Europe; this is 
the only species of the genus occurring in the Carpathian-Basin [2, 23]. Previous 
studies have focused on the antileukemic, antitumor, immunomodulator, antiproto-
zoal, molluscicidal, antihepatoma, and antinociceptive activities of Physalis spe-
cies [1]. 
Physalis species are known to contain different type of compounds, including 
physalins, alkaloids, flavonoids, carotenoids, vitamins and polysaccharides, among 
which physalins are the most active representative of secondary metabolites of the 
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genus. Physalins are steroidal constituents, they possess a 16,24-cyclo-13,14-secoer-
gostan framework, and are classified into types A and B according to the presence or 
absence of a C(14)-O-C(27) epoxy linkage, respectively (Fig. 1) [5, 19]. 
The first physalins were isolated from Physalis alkekengi var. franchetii (Mast) 
Makino [10, 13, 20, 21]. A large number of physalins have been characterized in the 
past years, mostly isolated from roots and aerial part of Physalis species [3, 7, 9, 17, 
18, 29, 30, 31]. Some physalins were known to exert cytotoxic activity against tumor 
cells [3, 8, 19]. Moreover, their antimalarial, antimycobacterial, antileishmanial, 
antinociceptive and chemopreventive activities were also demonstrated [4, 14, 22, 32].
Ph. alkekengi var. franchetii (Mast) Makino, Ph. angulata L., Ph. minima L., Ph. 
peruviana L. and Ph. pubescens L. are the most studied species and more than 30 
physalins have been described from these plants [11, 12, 16, 18, 26, 27, 28, 33]. In 
case of Ph. alkekengi, physalins D, L, N and O were isolated from the herb and calyx 
[6, 12, 28], and physalin D was found to be the main constituent. No comprehensive 
study has yet been reported about the content of this compound in the fruits and caly-
ces, therefore our aim was the isolation and quantitative determination of physalin D. 
With regard to the cytotoxic activity of physalins, the isolation process was guided by 
in vitro cytotoxic assay.
MATERIALS AND METHODS
General
1H-NMR and 13C-NMR spectra were recorded in DMSO-d6 and CDCl3 using TMS 
as internal standard at 500 and 125 MHz, respectively, on a Bruker Avance DRX500 
spectrometer. Centrifugal planar chromatographic (CPC) separation was performed 
using a Chromatotron® (Harrison Research Model 8924, USA) apparatus. HPLC 
separation was performed using a Waters Separation Module with a Waters 600 
Controller and Waters 2998 PDA detector on a LiChroCART RP18 column (5 µm, 
250 × 4 mm). Operation and data acquisition was performed using Empower Pro 
Software. All chemicals used for extraction and isolation were of analytical or HPLC-
Fig. 1. Structures of physalins
 type A physalin type B physalin
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grade (Molar Chemicals Kft, Budapest, Hungary or Merck, Darmstadt, Germany). 
Silica gel 60GF254 and TLC plates from Merck (Darmstadt, Germany) were applied.
Plant material
Mature and immature calices-with-fruits of Ph. alkekengi were collected from wild 
plants growing in the Mures district (Romania) in September 2015 and were dried at 
room temperature. A voucher specimen (No. 632/2015) has been deposited at the 
Herbarium of the Department of Pharmacognosy, University of Medicine and 
Pharmacy Târgu Mureş, Târgu Mureş, Romania. 
Extraction and isolation
A 200 g dried powdered mature fruit without calyx was macerated in 400 mL 50% 
MeOH overnight, then extracted with 2000 mL 50% MeOH by percolation, and con-
centrated in vacuum to approximately 400 mL. This extract was separated by sol-
vent–solvent extraction with n-hexane and then with chloroform. The chloroform 
extract was concentrated under reduced pressure and fractionated using different 
chromatographic methods. 
CPC separation of chloroform extract was performed on silica gel 60GF254 with 
gradient system of cyclohexane–EtOAc–EtOH–MeOH of increasing polarity gaining 
74 fractions. These fractions were monitored by TLC (silica gel 60F254, cyclohexane–
EtOAc 3:7) and the appropriate fractions were combined in fractions P1 – P7. 
Fractions P1 – P7 were tested for antiproliferative activity in order to find active 
fractions or compounds.
Antiproliferative assay
Antiproliferative effects were measured in vitro on three human cell lines (ECACC; 
Salisbury, UK): HeLa (cervix adenocarcinoma), MCF-7 (breast adenocarcinoma) and 
A431 (skin epidermoid carcinoma). The cells were cultivated in minimum essential 
medium (Gibco BRL; Paisley, UK) supplemented with 10% fetal bovine serum, 1% 
non-essential amino acids and an antibiotic mixture in a humified atmosphere of 5% 
CO2 at 37 °C. Cells were seeded into a 96-well plate at a density of 5000 cells/well. 
After the plate stood overnight, the medium containing the tested samples was added. 
Ten mg/mL stock solutions of the tested samples were prepared with dimethyl sulfox-
ide (DMSO) and the highest DMSO concentration of the medium (0.3%) did not have 
any significant effect on cell proliferation. After a 72-h incubation period, cytotoxic-
ity was measured with the MTT ([3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoli-
um bromide]) assay [23]. After a 4-h contact period, the precipitated formazan crys-
tals were dissolved in DMSO, and the absorbance was read at 545 nm with an ELISA 
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reader. Doxorubicin and cisplatin were used as positive controls; their IC50 values 
were 0.15 mM (HeLa), 0.28 mM (MCF-7), 0.15 mM (A431) for doxorubicin, and 
12.43 mM (HeLa), 9.63 mM (MCF-7), 2.84 mM (A431) for cisplatin.
Quantitative HPLC determination of physalin D
Column: LiChroCART RP18 (5 µm, 250 × 4 mm), mobile phase: acetonitrile–H2O 
(7:3), flow rate 0.7 mL/min, or acetonitrile–H2O (1:1), flow rate 0.4 mL/min; or 
MeOH–H2O (4:6), flow rate 0.7 mL/min, detection at 225.4 nm. Sample preparation: 
extracts were prepared from 1 g exactly weighted powdered plant materials with 25 
mL 50% MeOH by ultrasound assisted extraction for 15 minutes. The extracts were 
concentrated in vacuum to approximately ½ volumes. These extracts were purified 
with extraction of n-hexane (5 × 30 mL) in a separation funnel, followed by extraction 
with chloroform (5 × 30 mL). The chloroform phases were combined, evaporated and 
before HPLC analysis dissolved in 500 μL MeOH. Injected volume: 10 µL.
RESULTS AND DISCUSSION
Dried and ground fruits without calyces of Ph. alkekengi were extracted with 50% 
MeOH. After concentration, the extract was subjected to solvent–solvent partition, 
yielding n-hexane, CHCl3 and aqueous MeOH fractions. The antiproliferative effect 
of the CHCl3 extract was tested on HeLa and MCF-7 cell lines (Table 1). This extract 
was fractionated by CPC on silica gel and after TLC monitoring seven fractions 
(P1 – P7) were obtained. 
Antiproliferative effect of fractions P1 – P7 was tested on HeLa, MCF-7 and A431 
cell lines. The most active fraction was P3 on all cell lines, followed by P2 and P4 on 
HeLa and MCF-7 cells, and P4 on the A431 cell line (Table 2). 
A white crystalline substance (1) was isolated from fraction P3 by crystallization 
from cold MeOH. The structure of compound 1 was elucidated by means of 1H and 
13C NMR spectral analysis. The 13C NMR spectrum was recorded in CDCl3 and in 
DMSO, and showed a sterol-type molecule with 28 C atoms, suggesting physalin 
structure. The unambiguous NMR signal assignment was achieved with the aid of 
Table 1
In vitro antiproliferative activity of CHCl3 extract in MCF-7 and HeLa cells
Concentration 
μg/mL
MCF-7 HeLa
Growth inhibition % SEM Growth inhibition % SEM
 1 41.26 2.978 20.98 2.001
10 73.43 1.269 64.87 0.912
30 103.8 0.426 101.3 0.263
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Table 2
In vitro antiproliferative activity of fractions on HeLa, MCF-7 and A431 cell lines
Growth inhibition (%) ± SEM
HeLa MCF-7 A431
P1
10 µg/mL 36.95 ± 1.22 50.33 ± 1.67 <5*
30 µg/mL 49.05 ± 1.18 50.85 ± 2.83 42.94 ± 0.95
P2
10 µg/mL 16.60 ± 0.40 <5 <5
30 µg/mL 62.37 ± 1.15 61.47 ± 1.15 81.15 ± 0.78
P3
10 µg/mL 88.85 ± 0.42 87.84 ± 1.02 79.96 ± 1.06
30 µg/mL 96.74 ± 0.53 90.88 ± 1.30 85.67 ± 0.43
P4
10 µg/mL 25.89 ± 1.83 29.02 ± 2.73 29.61 ± 1.86
30 µg/mL 75.42 ± 0.50 95.69 ± 0.48 91.50 ± 0.51
P5
10 µg/mL 31.69 ± 1.71 26.01 ± 2.04 28.28 ± 2.78
30 µg/mL 42.02 ± 0.27 52.06 ± 1.82 46.15 ± 0.43
P6
10 µg/mL 16.84 ± 1.87 8.24 ± 0.68 <5
30 µg/mL 19.53 ± 1.65 32.16 ± 3.06 7.34 ± 0.80
P7
10 µg/mL 12.06 ± 2.27 <5 <5
30 µg/mL 15.76 ± 2.53 7.84 ± 2.44 <5
*Growth inhibition values of <5% are regarded as negligible and therefore not given numerically.
Table 3
1H NMR spectral data of physalin D (1) in DMSO-d6  
(500 MHz, δ ppm. multiplicity. coupling constant J in Hz)
Protons 1 Protons 1
H-2 5.77 dd (8.6; 2.4) H-12β 1.47 dd (16.2; 9.8)
H-3 6.62 dd (10; 2.9) H-13 5.70 s
H-4α 1.96 m H-16 2.77 s
H-4β 3.10 brd (19.4) H-19 1.11 s
5-OH 4.21 s H-21 1.81 s
H-6 3.49 m H-22 4.56 br
6-OH 4.87 d (4.1) H-23 1.95 d (12.7)
H-7 1.80 m H-23 2.10 m
H-7 1.80 m H-25 2.87 d (3.7)
H-8 2.20 dt (10.5; 4.5) H-27 3.58 d (12.9)
H-9 3.11 m H-27 4.25 dd (13.3; 4.4)
H-11 0.93 m H-28 1.16 s
H-12α 2.10 m
Physalin D from the fruit of  Physalis alkekengi 305
Acta Biologica Hungarica 68, 2017
2D-correlation spectroscopy (1H, 1H-COSY, HSQC and HMBC) (Table 3). Compound 
1 was identical in all of its spectral characteristics with physalin D (Fig. 2) [7]. 
Strong cytotoxic activity of this compound was reported by Magalhães et al. [15] 
Physalin D (1) displayed considerable cytotoxicity against nine tumor cell lines, 
showing IC50 values in the range of 0.51–4.47 µM in vitro. The in vivo tumor growth 
inhibitory activity was studied in mice transplanted with Sarcoma 180 tumor model. 
The physalin D (1) treatment afforded antitumor activity associated with reversible 
toxic effects to the liver and kidney [15].
Fig. 2. Structure of physalin D (1)
Fig. 3. Calibration curve with physalin D (1)
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Fig. 4. UV spectrum of physalin D (1)
Fig. 5. HPLC chromatogram of immature winter cherry calyx extract at 225.4 nm 
(physalin D RT = 19.23 min)
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Quantitative determination of physalin D in fruits and calyces
The quantitative determination of physalin D (1) was achieved by RP-HPLC-UV 
method with detection at 225.4 nm, the UV absorption maximum of the compound 
(Fig. 3). CHCl3 extracts were prepared from the dried mature and immature fruits and 
calyces with solvent–solvent partition of the 50% MeOH extract. The first step of the 
quantitative analysis was the determination of the calibration curve. As shown in 
Fig. 4, good linearity was obtained with R2 > 0.9972. HPLC separation was performed 
on LiChroCART RP18 reversed phase column with one of the acetonitrile-H2O mix-
tures as mobile phases (see Materials and Methods), depending on the composition 
of the extract, trying to obtain an efficient separation in the area of interest. A repre-
sentative chromatogram is presented in Fig. 5.
Fig. 6. Physalin D (1) content (%) of winter cherry fruit and calyx
Table 4
Physalin D (1) content of winter cherry fruit and calyx
Physalin D
g/100 g plant material
Immature fruits 0.0992 ± 0.0083
Mature fruits 0.0259 ± 0.0021
Immature calyx 0.7880 ± 0.0612
Mature calyx 0.2028 ± 0.016
Data expressed as mean ± SD of triplicate analysis.
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Among the studied samples, immature calyx showed the highest content of physa-
lin D (1) (0.7880 ± 0.0612 g%), while mature calyx contains 4 times less (0.2028 ± 0.016 
g%). The physalin D (1) content of the fruit is much lower; immature fruits contain 
0.0992 ± 0.0083 g% physalin D and mature fruits 0.0259 ± 0.0021 g% (Table 4, 
Fig. 6).
In conclusion, with combination of different chromatographic methods physalin D 
(1) was isolated from the 50% MeOH extract of Ph. alkekengi fruits. The structure 
was elucidated by 1H and 13C NMR spectral analysis with the aid of 2D-correlation 
spectroscopy (1H, 1H-COSY, HSQC and HMBC) and comparison with literature data. 
The quantity of physalin D (1) was evaluated in fruits and calyces and cytotoxic 
activity was tested on three cancer cell lines (HeLa, MCF-7 and A431). The occur-
rence and quantitative determination of physalin D in fruits of Ph. alkekengi is 
reported here for the first time. 
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